(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
Triple polar vortex to plunge central and eastern U.S. into Arctic cold through mid-December- Safeguarding Your Senior Protection Against Extortion and Tricks.
- Bolsonaro says hallucinatory effects of meds made him tamper with ankle tag
- What's the Fate of 5G Innovation?
- 6 Exemplary Mexican Dishes
- I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- High Court freezes government move to shutter Army Radio pending ruling
- Why do people get headaches and migraines? A child neurologist explains the science of head pain and how to treat it
- Figure out How to Utilize Your Web based Advertising Degree to Break into the Tech Business
